Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
14.94
-0.44 (-2.86%)
At close: Mar 5, 2026, 4:00 PM EST
15.00
+0.06 (0.40%)
Pre-market: Mar 6, 2026, 8:01 AM EST
Summit Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Summit Therapeutics stock have an average target of 33.38, with a low estimate of 12 and a high estimate of 44. The average target predicts an increase of 123.43% from the current stock price of 14.94.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Summit Therapeutics stock from 15 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 9 | 9 | 8 | 7 | 7 |
| Buy | 5 | 5 | 5 | 4 | 4 | 4 |
| Hold | 1 | 1 | 2 | 3 | 3 | 3 |
| Sell | 2 | 2 | 2 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 17 | 18 | 16 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $30 | Strong Buy | Maintains | $40 → $30 | +100.80% | Feb 24, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +167.74% | Feb 2, 2026 |
| Citizens | Citizens | Buy Reiterates $40 | Buy | Reiterates | $40 | +167.74% | Jan 30, 2026 |
| Barclays | Barclays | Sell → Hold Upgrades $16 → $18 | Sell → Hold | Upgrades | $16 → $18 | +20.48% | Dec 17, 2025 |
| Wolfe Research | Wolfe Research | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Nov 18, 2025 |
Financial Forecast
Revenue This Year
9.71M
Revenue Next Year
110.00M
from 9.71M
Increased by 1,032.97%
EPS This Year
-1.02
from -1.44
EPS Next Year
-1.01
from -1.02
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 61.0M | 377.9M | |||
| Avg | 9.7M | 110.0M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 3,792.0% | |||
| Avg | - | 1,033.0% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.60 | -0.61 | |||
| Avg | -1.02 | -1.01 | |||
| Low | -1.60 | -1.65 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.